Intraventricular colistin sulphate as a last resort therapy in a patient with multidrug-resistant Acinetobacter baumannii induced post-neurosurgical ventriculitis

被引：16

作者：

Yu, Xu-Ben ^{[1
]}

Huang, Yue-Yue ^{[2
]}

Zhang, Xiao-Shan ^{[1
,3
]}

Wang, Yu-Zhen ^{[1
,3
]}

Shi, Da-Wei ^{[1
]}

Zhang, Chun-Hong ^{[1
]}

Chen, Jie ^{[2
]}

Wang, Xiao-Rong ^{[2
]}

Lin, Guan-Yang ^{[1
]}

机构：

[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pharm, Wenzhou, Peoples R China

[2] Wenzhou Med Univ, Affiliated Hosp 1, Intens Care Unit, Wenzhou, Peoples R China

[3] Wenzhou Med Univ, Dept Pharm, Wenzhou, Peoples R China

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2022年 / 88卷 / 07期

关键词：

Acinetobacter baumannii; colistin sulphate; intraventricular; ventriculitis; INFECTIOUS-DISEASES SOCIETY; COLISTIMETHATE SODIUM; PHARMACOKINETICS; PHARMACOLOGY; TIGECYCLINE; MENINGITIS; GUIDELINES; AMPICILLIN; SULBACTAM;

D O I：

10.1111/bcp.15238

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Limited therapeutic options exist for multidrug-resistant/extensively drug-resistant Acinetobacter baumannii (MDR/XDR-Ab) meningitis/ventriculitis. A combination of intravenous and intraventricular (IVT)/intrathecal (IT) polymyxins achieves good therapeutic outcomes for cases of healthcare-associated MDR/XDR-Ab meningitis/ventriculitis. Colistin is commercially available as colistin sulphate and its sulphomethylated derivative. However, the effect and safety of colistin sulphate in the treatment of MDR/XDR-Ab meningitis/ventriculitis has not been reported. We report on a 66-year-old male patient who developed post-neurosurgical ventriculitis caused by MDR-Ab. IVT concomitant intravenous colistin sulphate was used as a last-resort antimicrobial therapy, the patient's ventriculitis was dramatically improved, and the concentrations of CSF colistin were higher than the MIC breakpoint throughout the treatment. Meanwhile, no nephrotoxicity or neurotoxicity was observed during the treatment.

引用

页码：3490 / 3494

页数：5

共 20 条

[1] Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center [J].

Akajagbor, Darowan S. ;

Wilson, Sharon L. ;

Shere-Wolfe, Kapana D. ;

Dakum, Paul ;

Charurat, Manhattan E. ;

Gilliam, Bruce L. .

CLINICAL INFECTIOUS DISEASES, 2013, 57 (09) :1300-1303

[2] SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS [J].

BARNETT, M ;

BUSHBY, SRM ;

WILKINSON, S .

BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1964, 23 (03) :552-+

[3] THE CHEMOTHERAPY AND PHARMACOLOGY OF THE POLYMYXINS [J].

BROWNLEE, G ;

BUSHBY, SRM ;

SHORT, EI .

BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1952, 7 (01) :170-188

[4] Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis [J].

Cawley, MJ ;

Suh, C ;

Lee, S ;

Ackerman, BH .

PHARMACOTHERAPY, 2002, 22 (04) :527-532

[5]

Chen Y., 2013, SHANGHAI PHARMA, V34, P16, DOI 10.3969/j.issn.1006-1533.2013.13.007

[6]

CLSI, 2019, CLSI document M100, V29th

[7] Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers [J].

Couet, W. ;

Gregoire, N. ;

Gobin, P. ;

Saulnier, P. J. ;

Frasca, D. ;

Marchand, S. ;

Mimoz, O. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) :875-879

[8] A case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial Acinetobacter baumannii infection [J].

Deng, Zi-Wei ;

Wang, Jin ;

Qiu, Cheng-Feng ;

Yang, Yi ;

Shi, Zhi-Hua ;

Zhou, Jian-Liang .

MEDICINE, 2019, 98 (15)

[9] Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence [J].

Falagas, Matthew E. ;

Vardakas, Konstantinos Z. ;

Roussos, Nikolaos S. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (03) :231-241

[10]

FOULDS G, 1986, REV INFECT DIS, V8, pS503

← 1 2 →